Michael Bass: The Most Under Prescribed Therapy in Colorectal Cancer – And it’s not a Drug
Michael Bass, Founding Medical Director of Oshi Health, shared a post on LinkedIn:
“This might be the most under prescribed therapy in colorectal cancer. And it’s not a drug.
A new NEJM phase 3 trial followed nearly 900 patients with resected colon cancer. All had completed chemo. Half were coached to walk briskly for 150 minutes per week.
8 years later, when compared to the non-exercise group:
- 37% lower risk of death.
- +7% overall survival.
- Better energy, mobility, and strength.
Meanwhile, many CRC drugs approved over the past 10 years have 2–3 month survival gains, cost $100 k plus, and have side serious side effects.
Incredible study that has major implications on how we view cancer care!!”
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer.
Authors:Kerry S. Courneya, Janette L. Vardy, Christopher J. O’Callaghan, Sharlene Gill, Christine M. Friedenreich, Rebecca K.S. Wong, Haryana M. Dhillon, Victoria Coyle, Neil S. Chua, Derek J. Jonker, Philip J. Beale, Kamal Haider, Patricia A. Tang, Tony Bonaventura, Ralph Wong, Howard J. Lim, Matthew E. Burge, Stacey Hubay, Michael Sanatani, Kristin L. Campbell, Fernanda Z. Arthuso, Jane Turner, Ralph M. Meyer, Michael Brundage, Patti O’Brien, Dongsheng Tu, Christopher M. Booth.
You can read the full article on The New England Journal of Medicine.
“This study has been making the headlines following ASCO. This is very well deserved but in no way surprising to those of us who work in integrative oncology where exercise oncology is a part of our standard of care. Every patient at our practice, Synthesis Clinic, gets counselled about movement by our integrative oncology physicians, as well as being offered access to specialist physiotherapy and cancer exercise support.
Now what we really need across the board are proper investment within the public healthcare system and reimbursement schemes from private insurers to make care like this consistently accessible. This is an essential, not a ‘nice to have’.
More posts featuring Michael Bass.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023